

Dr. Shah is a Board-Certified Adult Endocrinologist and an Associate Professor at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus. His research is focused on improving glycemic control and reducing complications, with special interest in fracture prevention, in people with type 1 diabetes.

Dr. Shah has extensive experience in conducting clinical trials in field of diabetes. He has been the PI for many multicenter industry-sponsored, investigator-initiated, and nonprofit-funded clinical trials of diabetes technologies and therapeutics. He has been a part of landmark research such as REPLACE-BG, WISDM, Artificial pancreas Cambridge (ApCam), OP5 HCL, and Dexcom G6 pivotal that led to FDA approval of newer devices and changed the type 1 diabetes management. Moreover, his interest in understanding the effect of diabetes on bone fragility had led to two NIH-funded studies investigating effect of long-standing T1D on bone tissue material properties (AR075099) and factors affecting bone density (vBMD), bone mechanical properties in adults with type 1 diabetes (DK122554).

Dr. Shah has served on many leadership positions such as steering committee member for T1D Exchange Clinic Registry (2016-2017), Communication director for diabetes technology interest group at the American Diabetes Association (2019-2020), Ad hoc member of 79th AD annual meeting planning subcommittee for Diabetes Technology, and American College of Endocrinology Self-Assessment Program writing committee member (2020-2021). He is a recipient of prestigious AACE Rising Start in Endocrinology award (2021). He is well published with over 100 research publications including original article, invited reviews, editorials, and book chapters. He is reviewer for many peer-reviewed indexed journals and grant reviewer for JDRF, ADA and NIH.